Cargando…

Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial

AIM: The neural cardiac therapy for heart failure (NECTAR-HF) was a randomized sham-controlled trial designed to evaluate whether a single dose of vagal nerve stimulation (VNS) would attenuate cardiac remodelling, improve cardiac function and increase exercise capacity in symptomatic heart failure p...

Descripción completa

Detalles Bibliográficos
Autores principales: Zannad, Faiez, De Ferrari, Gaetano M., Tuinenburg, Anton E., Wright, David, Brugada, Josep, Butter, Christian, Klein, Helmut, Stolen, Craig, Meyer, Scott, Stein, Kenneth M., Ramuzat, Agnes, Schubert, Bernd, Daum, Doug, Neuzil, Petr, Botman, Cornelis, Castel, Maria Angeles, D'Onofrio, Antonio, Solomon, Scott D., Wold, Nicholas, Ruble, Stephen B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4328197/
https://www.ncbi.nlm.nih.gov/pubmed/25176942
http://dx.doi.org/10.1093/eurheartj/ehu345
_version_ 1782357204146323456
author Zannad, Faiez
De Ferrari, Gaetano M.
Tuinenburg, Anton E.
Wright, David
Brugada, Josep
Butter, Christian
Klein, Helmut
Stolen, Craig
Meyer, Scott
Stein, Kenneth M.
Ramuzat, Agnes
Schubert, Bernd
Daum, Doug
Neuzil, Petr
Botman, Cornelis
Castel, Maria Angeles
D'Onofrio, Antonio
Solomon, Scott D.
Wold, Nicholas
Ruble, Stephen B.
author_facet Zannad, Faiez
De Ferrari, Gaetano M.
Tuinenburg, Anton E.
Wright, David
Brugada, Josep
Butter, Christian
Klein, Helmut
Stolen, Craig
Meyer, Scott
Stein, Kenneth M.
Ramuzat, Agnes
Schubert, Bernd
Daum, Doug
Neuzil, Petr
Botman, Cornelis
Castel, Maria Angeles
D'Onofrio, Antonio
Solomon, Scott D.
Wold, Nicholas
Ruble, Stephen B.
author_sort Zannad, Faiez
collection PubMed
description AIM: The neural cardiac therapy for heart failure (NECTAR-HF) was a randomized sham-controlled trial designed to evaluate whether a single dose of vagal nerve stimulation (VNS) would attenuate cardiac remodelling, improve cardiac function and increase exercise capacity in symptomatic heart failure patients with severe left ventricular (LV) systolic dysfunction despite guideline recommended medical therapy. METHODS: Patients were randomized in a 2 : 1 ratio to receive therapy (VNS ON) or control (VNS OFF) for a 6-month period. The primary endpoint was the change in LV end systolic diameter (LVESD) at 6 months for control vs. therapy, with secondary endpoints of other echocardiography measurements, exercise capacity, quality-of-life assessments, 24-h Holter, and circulating biomarkers. RESULTS: Of the 96 implanted patients, 87 had paired datasets for the primary endpoint. Change in LVESD from baseline to 6 months was −0.04 ± 0.25 cm in the therapy group compared with −0.08 ± 0.32 cm in the control group (P = 0.60). Additional echocardiographic parameters of LV end diastolic dimension, LV end systolic volume, left ventricular end diastolic volume, LV ejection fraction, peak V0(2), and N-terminal pro-hormone brain natriuretic peptide failed to show superiority compared to the control group. However, there were statistically significant improvements in quality of life for the Minnesota Living with Heart Failure Questionnaire (P = 0.049), New York Heart Association class (P = 0.032), and the SF-36 Physical Component (P = 0.016) in the therapy group. CONCLUSION: Vagal nerve stimulation as delivered in the NECTAR-HF trial failed to demonstrate a significant effect on primary and secondary endpoint measures of cardiac remodelling and functional capacity in symptomatic heart failure patients, but quality-of-life measures showed significant improvement.
format Online
Article
Text
id pubmed-4328197
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-43281972015-02-26 Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial Zannad, Faiez De Ferrari, Gaetano M. Tuinenburg, Anton E. Wright, David Brugada, Josep Butter, Christian Klein, Helmut Stolen, Craig Meyer, Scott Stein, Kenneth M. Ramuzat, Agnes Schubert, Bernd Daum, Doug Neuzil, Petr Botman, Cornelis Castel, Maria Angeles D'Onofrio, Antonio Solomon, Scott D. Wold, Nicholas Ruble, Stephen B. Eur Heart J FASTTrack Esc Hot Line AIM: The neural cardiac therapy for heart failure (NECTAR-HF) was a randomized sham-controlled trial designed to evaluate whether a single dose of vagal nerve stimulation (VNS) would attenuate cardiac remodelling, improve cardiac function and increase exercise capacity in symptomatic heart failure patients with severe left ventricular (LV) systolic dysfunction despite guideline recommended medical therapy. METHODS: Patients were randomized in a 2 : 1 ratio to receive therapy (VNS ON) or control (VNS OFF) for a 6-month period. The primary endpoint was the change in LV end systolic diameter (LVESD) at 6 months for control vs. therapy, with secondary endpoints of other echocardiography measurements, exercise capacity, quality-of-life assessments, 24-h Holter, and circulating biomarkers. RESULTS: Of the 96 implanted patients, 87 had paired datasets for the primary endpoint. Change in LVESD from baseline to 6 months was −0.04 ± 0.25 cm in the therapy group compared with −0.08 ± 0.32 cm in the control group (P = 0.60). Additional echocardiographic parameters of LV end diastolic dimension, LV end systolic volume, left ventricular end diastolic volume, LV ejection fraction, peak V0(2), and N-terminal pro-hormone brain natriuretic peptide failed to show superiority compared to the control group. However, there were statistically significant improvements in quality of life for the Minnesota Living with Heart Failure Questionnaire (P = 0.049), New York Heart Association class (P = 0.032), and the SF-36 Physical Component (P = 0.016) in the therapy group. CONCLUSION: Vagal nerve stimulation as delivered in the NECTAR-HF trial failed to demonstrate a significant effect on primary and secondary endpoint measures of cardiac remodelling and functional capacity in symptomatic heart failure patients, but quality-of-life measures showed significant improvement. Oxford University Press 2015-02-14 2014-08-31 /pmc/articles/PMC4328197/ /pubmed/25176942 http://dx.doi.org/10.1093/eurheartj/ehu345 Text en © The Author 2014. Published by Oxford University Press on behalf of the European Society of Cardiology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle FASTTrack Esc Hot Line
Zannad, Faiez
De Ferrari, Gaetano M.
Tuinenburg, Anton E.
Wright, David
Brugada, Josep
Butter, Christian
Klein, Helmut
Stolen, Craig
Meyer, Scott
Stein, Kenneth M.
Ramuzat, Agnes
Schubert, Bernd
Daum, Doug
Neuzil, Petr
Botman, Cornelis
Castel, Maria Angeles
D'Onofrio, Antonio
Solomon, Scott D.
Wold, Nicholas
Ruble, Stephen B.
Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial
title Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial
title_full Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial
title_fullStr Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial
title_full_unstemmed Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial
title_short Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial
title_sort chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the neural cardiac therapy for heart failure (nectar-hf) randomized controlled trial
topic FASTTrack Esc Hot Line
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4328197/
https://www.ncbi.nlm.nih.gov/pubmed/25176942
http://dx.doi.org/10.1093/eurheartj/ehu345
work_keys_str_mv AT zannadfaiez chronicvagalstimulationforthetreatmentoflowejectionfractionheartfailureresultsoftheneuralcardiactherapyforheartfailurenectarhfrandomizedcontrolledtrial
AT deferrarigaetanom chronicvagalstimulationforthetreatmentoflowejectionfractionheartfailureresultsoftheneuralcardiactherapyforheartfailurenectarhfrandomizedcontrolledtrial
AT tuinenburgantone chronicvagalstimulationforthetreatmentoflowejectionfractionheartfailureresultsoftheneuralcardiactherapyforheartfailurenectarhfrandomizedcontrolledtrial
AT wrightdavid chronicvagalstimulationforthetreatmentoflowejectionfractionheartfailureresultsoftheneuralcardiactherapyforheartfailurenectarhfrandomizedcontrolledtrial
AT brugadajosep chronicvagalstimulationforthetreatmentoflowejectionfractionheartfailureresultsoftheneuralcardiactherapyforheartfailurenectarhfrandomizedcontrolledtrial
AT butterchristian chronicvagalstimulationforthetreatmentoflowejectionfractionheartfailureresultsoftheneuralcardiactherapyforheartfailurenectarhfrandomizedcontrolledtrial
AT kleinhelmut chronicvagalstimulationforthetreatmentoflowejectionfractionheartfailureresultsoftheneuralcardiactherapyforheartfailurenectarhfrandomizedcontrolledtrial
AT stolencraig chronicvagalstimulationforthetreatmentoflowejectionfractionheartfailureresultsoftheneuralcardiactherapyforheartfailurenectarhfrandomizedcontrolledtrial
AT meyerscott chronicvagalstimulationforthetreatmentoflowejectionfractionheartfailureresultsoftheneuralcardiactherapyforheartfailurenectarhfrandomizedcontrolledtrial
AT steinkennethm chronicvagalstimulationforthetreatmentoflowejectionfractionheartfailureresultsoftheneuralcardiactherapyforheartfailurenectarhfrandomizedcontrolledtrial
AT ramuzatagnes chronicvagalstimulationforthetreatmentoflowejectionfractionheartfailureresultsoftheneuralcardiactherapyforheartfailurenectarhfrandomizedcontrolledtrial
AT schubertbernd chronicvagalstimulationforthetreatmentoflowejectionfractionheartfailureresultsoftheneuralcardiactherapyforheartfailurenectarhfrandomizedcontrolledtrial
AT daumdoug chronicvagalstimulationforthetreatmentoflowejectionfractionheartfailureresultsoftheneuralcardiactherapyforheartfailurenectarhfrandomizedcontrolledtrial
AT neuzilpetr chronicvagalstimulationforthetreatmentoflowejectionfractionheartfailureresultsoftheneuralcardiactherapyforheartfailurenectarhfrandomizedcontrolledtrial
AT botmancornelis chronicvagalstimulationforthetreatmentoflowejectionfractionheartfailureresultsoftheneuralcardiactherapyforheartfailurenectarhfrandomizedcontrolledtrial
AT castelmariaangeles chronicvagalstimulationforthetreatmentoflowejectionfractionheartfailureresultsoftheneuralcardiactherapyforheartfailurenectarhfrandomizedcontrolledtrial
AT donofrioantonio chronicvagalstimulationforthetreatmentoflowejectionfractionheartfailureresultsoftheneuralcardiactherapyforheartfailurenectarhfrandomizedcontrolledtrial
AT solomonscottd chronicvagalstimulationforthetreatmentoflowejectionfractionheartfailureresultsoftheneuralcardiactherapyforheartfailurenectarhfrandomizedcontrolledtrial
AT woldnicholas chronicvagalstimulationforthetreatmentoflowejectionfractionheartfailureresultsoftheneuralcardiactherapyforheartfailurenectarhfrandomizedcontrolledtrial
AT rublestephenb chronicvagalstimulationforthetreatmentoflowejectionfractionheartfailureresultsoftheneuralcardiactherapyforheartfailurenectarhfrandomizedcontrolledtrial